S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
MarketsFN
Home/Hedge Funds/Baker Bros Advisors/Q3 2020

Baker Bros Advisors

Period: Q3 2020 Β· Filed: 2020-11-16
View on SEC EDGAR β†—
AUM
$25.03B
Total portfolio value
Positions
120
Reported securities
Top Holding
SGEN
37.0% $9.25B
QoQ Changes
+8 / -8
new Β· exited
⚠️13F Filing Disclosure

AUM figures shown are calculated by summing the reported market value of all positions in SEC 13F-HR filings β€” not the fund's actual assets under management.

  • Excludes cash, bonds, private equity, short positions, and foreign-listed stocks not required to be reported.
  • For PUT and CALL options, the reported Value is the notional value of the underlying shares β€” not the option premium paid. This significantly overstates the actual capital at risk.
  • Actual fund AUM is typically higher and includes strategies, instruments, and positions that never appear in a 13F.
  • 13F filings cover institutional managers with β‰₯$100M in 13F securities. Positions reflect end-of-quarter holdings, disclosed up to 45 days after the period ends.

Data sourced from SEC EDGAR. This tracker is for informational purposes only and does not constitute investment advice.

Portfolio Holdings

Top 30 positions

⚠️ Performance % calculated from filing date ( 2020-11-16) shown is the underlying stock price movement β€” not the derivative's P&L.
TickerIssuerNotionalPort %@ FilingNow (EOD)Since FilingAllocation
SGENSeagen Inc.$9.25B36.96%β€”β€”
37.0%
ONCBeiGene, Ltd.$3.81B15.22%$286.44$297.65+3.9%
15.2%
INCYIncyte Corporation$2.87B11.47%$89.74$116.86+30.2%
11.5%
ACADACADIA Pharmaceuticals Inc.$1.73B6.91%$41.25$25.97-37.0%
6.9%
ALXNAlexion Pharmaceuticals, Inc.$1.00B4.01%β€”β€”
4.0%
KODKodiak Sciences Inc.$731.4M2.92%$59.21$38.54-34.9%
2.9%
BMRNBioMarin Pharmaceutical Inc.$577.4M2.31%$76.08$58.99-22.5%
2.3%
ASNDAscendis Pharma A/S$546.3M2.18%$154.32$274.50+77.9%
2.2%
NVTAQInvitae Corporation$513.7M2.05%β€”β€”
2.0%
MYOKMyoKardia, Inc.$410.3M1.64%β€”β€”
1.6%
PRLDPrelude Therapeutics Incorporated$304.9M1.22%$30.13$4.91-83.7%
1.2%
ARGXargenx SE$267.6M1.07%$262.52$939.68+257.9%
1.1%
MRTXMirati Therapeutics, Inc.$234.1M0.94%β€”β€”
0.9%
IGMSIGM Biosciences, Inc.$232.1M0.93%β€”β€”
0.9%
EXASExact Sciences Corporation$188.2M0.75%β€”β€”
0.8%
MDGLMadrigal Pharmaceuticals, Inc.$178.0M0.71%$118.73$528.10+344.8%
0.7%
AMRNXXXXAmarin Corporation plc$134.8M0.54%β€”β€”
0.5%
HRTXHeron Therapeutics, Inc.$88.8M0.35%$14.82$0.44-97.0%
0.3%
FMTXForma Therapeutics Holdings, Inc.$88.3M0.35%β€”β€”
0.3%
CERSCerus Corporation$85.8M0.34%$6.26$3.16-49.5%
0.3%
ZYMEZymeworks Inc.$79.6M0.32%$46.58$26.31-43.5%
0.3%
INSMInsmed Incorporated$73.0M0.29%$32.14$111.60+247.2%
0.3%
AXSMAxsome Therapeutics, Inc.$68.4M0.27%$71.25$244.31+242.9%
0.3%
NBIXNeurocrine Biosciences, Inc.$65.1M0.26%$96.16$174.26+81.2%
0.3%
KYMRKymera Therapeutics, Inc.$63.3M0.25%$32.31$113.51+251.3%
0.3%
NRIXNurix Therapeutics, Inc.$62.5M0.25%$34.91$23.97-31.3%
0.3%
ALLKAllakos Inc.$56.9M0.23%β€”β€”
0.2%
ADCTADC Therapeutics SA$55.7M0.22%$32.99$1.19-96.4%
0.2%
RYTMRhythm Pharmaceuticals, Inc.$53.5M0.21%$21.67$114.17+426.9%
0.2%
HZNPHorizon Therapeutics Public Ltd Co$51.8M0.21%β€”β€”
0.2%

Quarter-on-Quarter Activity

Q3 2020 vs. Q2 2020

New Positions (8)

TickerIssuerNotionalSince Filing
SGENSeagen Inc.$9.25B
PRLDPrelude Therapeutics Incorporated$304.9M-83.7%
KYMRKymera Therapeutics, Inc.$63.3M+251.3%
NRIXNurix Therapeutics, Inc.$62.5M-31.3%
PACBPacific Biosciences of California, Inc.$32.1M
Invitae Corporation$16.9M
ATHAAthira Pharma, Inc.$16.3M
HRMYHarmony Biosciences Holdings, Inc.$13.6M

Exited Positions (8)

TickerIssuerNotional
SGENXXXXSeattle Genetics, Inc.$8.03B
PRNBPrincipia Biopharma Inc.$94.5M
TCDAQTricida, Inc.$21.6M
AIMTAimmune Therapeutics, Inc.$11.3M
ABEOAbeona Therapeutics Inc.$4.6M
ARYAARYA Sciences Acquisition Corp.$2.4M
MTNBMatinas BioPharma Holdings, Inc.$1.6M
MRKRMarker Therapeutics, Inc.$0.5M

Increased (8)

TickerIssuerNotionalShares Ξ”Since Filing
REPLReplimune Group, Inc.$4.6M+3918.4%
GBTGlobal Blood Therapeutics, Inc.$47.8M+1858.2%
HZNPHorizon Therapeutics Public Ltd Co$40.7M+233.2%
CBAYCymabay Therapeutics, Inc.$18.2M+113.6%
ALBOAlbireo Pharma, Inc.$8.6M+48.8%
OVIDOvid Therapeutics Inc.$0.0M+28.9%
ONCBeiGene, Ltd.$1.59B+12.9%+3.9%
NLTXNeoleukin Therapeutics, Inc.$-10.5M+12.5%

Trimmed (8)

TickerIssuerNotionalShares Ξ”Since Filing
SNSSSunesis Pharmaceuticals, Inc.$-0.1M-90.5%
EVFMEvofem Biosciences, Inc.$-3.0M-69.6%
ARAVAravive, Inc.$-2.5M-68.9%
LPTXLeap Therapeutics, Inc.$-0.9M-42.8%
APLTApplied Therapeutics, Inc.$-1.6M-42.3%
IMMUImmunomedics, Inc.$8.5M-28.0%
NBIXNeurocrine Biosciences, Inc.$-45.5M-25.4%+81.2%
GWPHGW Pharmaceuticals plc$-9.2M-25.0%
← Back to Hedge Funds